Kent Imaging
Kent Imaging designs and markets handheld near-infrared (SnapshotNIR) and fluorescence (SnapshotGLO) imaging devices that assess tissue oxygenation and bacterial bioburden for wound care, vascular, and reconstructive surgery clinicians, selling direct in North America and via exclusive regional distributors across Europe and the Middle East.
- Company typePrivate
- Founded2006
- HeadquartersCalgary, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kent Imaging does
Kent Imaging is a Calgary-based, privately held medical device company founded in 2006 that designs, manufactures, and markets multispectral imaging systems for tissue oxygenation and bacterial bioburden assessment. Its flagship product, SnapshotNIR, is a handheld near-infrared spectroscopy (NIRS) device that measures tissue oxygen saturation (StO2) and hemoglobin trends in microcirculation in under two seconds at the bedside, with a proprietary melanin-compensating algorithm enabling accurate measurement across diverse skin tones. Its second product, SnapshotGLO, launched in September 2025, provides portable fluorescence-based bacterial bioburden assessment. Together the two devices form the 'Snapshot Suite,' which the company markets as a dual-insight diagnostic workflow for chronic wounds, diabetic foot ulcers, pressure injuries, reconstructive surgery flap viability, and peripheral arterial disease screening.
The company operates a hybrid go-to-market model: direct field and inside sales in North America, paired with exclusive regional distributors internationally — MediMax Global in the UK and Ireland, PRHOINSA in Spain, R-Cure Medical in Israel, and Roots Pharmaceutical across Iraq and the Gulf Cooperation Council. Kent Imaging sells primarily to wound care specialists, limb preservation programs, vascular surgeons, and plastic/reconstructive surgeons through hospital and clinic procurement. Pricing is quote-based and not publicly disclosed, consistent with enterprise medical device sales. The company holds FDA 510(k) clearance (2017, updated to KD205 in 2024), CE Marking (September 2025), MHRA registration (2025), and Health Canada approval (December 2025), and has built EHR integrations with Epic, DocNow, WoundExpert, and CarePICS.
Kent Imaging is backed by TVM Life Science following a $15 million financing in February 2021, the largest disclosed funding round, alongside earlier capital from the Western Innovation (WINN) Initiative and founder Don Chapman. The company is led by CEO Pierre Lemire (joined 2015; previously founded Calgary Scientific) following the passing of founder Don Chapman in February 2025. A meaningful near-term overhang is the U.S. International Trade Commission investigation instituted January 28, 2026 against the SnapshotGLO product based on a MolecuLight complaint alleging infringement of U.S. Patent No. 10,438,356, which Kent Imaging is contesting.
Kent Imaging firmographics
Firmographics- Name
- Kent Imaging
- Legal name
- Kent Imaging Inc.
- Website
- https://kentimaging.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kent Imaging designs and markets handheld near-infrared (SnapshotNIR) and fluorescence (SnapshotGLO) imaging devices that assess tissue oxygenation and bacterial bioburden for wound care, vascular, and reconstructive surgery clinicians, selling direct in North America and via exclusive regional distributors across Europe and the Middle East.
- Ownership category
- akta.pro rank
Kent Imaging industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industries
- Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Kent Imaging is headquartered
LocationHeadquarters
- HQ city
- Calgary
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Kent Imaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Device Sales (SnapshotNIR and SnapshotGLO): Kent Imaging generates revenue from the sale of its near-infrared tissue oxygenation imaging devices. The company sells directly and through distribution partners internationally. Device pricing appears to be quote-based with consideration for healthcare facility procurement processes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Device purchase model - no public pricing disclosed |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels5 records
Kent Imaging product offering
Product offeringCore offering
Kent Imaging designs, manufactures, and markets near-infrared spectroscopy (NIRS) imaging devices, primarily the handheld SnapshotNIR device that measures tissue oxygen saturation (StO2) and hemoglobin trends in microcirculation, and the SnapshotGLO fluorescence imaging device for non-invasive bacterial bioburden detection at the bedside. These devices serve wound care, vascular disease assessment, and reconstructive surgery applications in healthcare facilities.
Product overview
Kent Imaging offers two core diagnostic imaging products: SnapshotNIR and SnapshotGLO. SnapshotNIR is a handheld near-infrared spectroscopy device that measures tissue oxygen saturation (StO2) and viability, used in wound care, vascular screening, and reconstructive surgery. SnapshotGLO is a portable fluorescence imaging device for bacterial bioburden detection at point-of-care. Together they form the 'Snapshot Suite' providing dual imaging insights revealing two key barriers to healing: low tissue oxygenation and elevated bacterial bioburden.
Differentiator
Problem solved
Functional benefit
Brands
- SnapshotNIR: Near-infrared tissue oxygenation imaging device that measures oxygenated and deoxygenated hemoglobin to assess tissue viability in real time, designed for wound care, vascular, and surgical applications.
- SnapshotGLO
- Snapshot Suite
Products and services
- SnapshotNIR Handheld near-infrared spectroscopy device that measures oxygenated and deoxygenated hemoglobin to assess tissue oxygen saturation (StO2) and tissue viability in real time. Used for wound care, vascular disease screening, and surgical applications. Captures data in under 2 seconds at the bedside.
- SnapshotGLO Portable bacteria assessment device that non-invasively detects bacterial bioburden at the bedside using fluorescence imaging technology for point-of-care diagnostic imaging.
Companies that use Kent Imaging
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Kent Imaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability2 records
Feature5 records
Kent Imaging partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered key regional and strategic.
- Roots Pharmaceutical Company W.L.L.key regionalKent Imaging appointed Roots Pharmaceutical as authorized distributor of SnapshotNIR across Iraq and the Gulf Cooperation Council countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and UAE). The agreement brings non-invasive tissue oxygenation imaging technology to a region with high rates of diabetes and diabetic foot complications. Both companies will initially focus on wound care, vascular disease, and diabetes-related complications through Roots' established hospital and healthcare system relationships across more than ten markets in the MENA region.
- PRHOINSAkey regionalPRHOINSA serves as distribution partner for Kent Imaging's commercial launch of SnapshotNIR in Spain following CE Marking approval. The partnership represents a key milestone in Kent Imaging's European expansion strategy, enabling local market access for the near-infrared tissue oxygenation device.
- New Horizon Medical SolutionsstrategicNew Horizon Medical Solutions is identified as a partnership supporting Kent Imaging's positioning for expanded global reach, working alongside TVM Life Science backing.
- MediMax Globalkey regionalMediMax Global appointed as exclusive distributor for Kent Imaging's SnapshotNIR tissue oxygenation imaging device in the UK and Eire. The partnership aims to expand access to this medical technology supporting clinicians in wound care management by providing rapid tissue health assessments.
- R-Cure Medicalkey regionalR-Cure Medical in Israel received authorization to distribute Kent Imaging's updated SnapshotNIR KD205 device, which measures tissue oxygenation and viability. The product is particularly used in breast reconstruction surgery and wound care, with emphasis on achieving better clinical outcomes and expanding accessibility in the Israeli market.
Scale indicators4 records
Recent moves10 records
Expansion highlights5 records
Kent Imaging competitors and assessment
Company assessmentDirect peers
- MolecuLight: MolecuLight manufactures the i:X handheld fluorescence imaging device for real-time visualization of bacteria in wounds — directly competing with Kent's SnapshotGLO. MolecuLight is also the complainant in the active ITC patent investigation against Kent's SnapshotGLO product.
- HyperMed Imaging: HyperMed Imaging produces HyperView, a hyperspectral imaging system that assesses tissue oxygenation and perfusion in wounds and tissue — directly comparable to Kent's SnapshotNIR in core technology (spectral tissue imaging) and clinical use case (wound care oxygenation assessment).
- WoundVision: WoundVision offers the Snapshot (different brand) near-infrared spectroscopy imaging system for tissue oxygenation assessment in chronic wound management, directly competing with Kent's SnapshotNIR in the wound-care clinician market.
- Spectros Corporation: Spectros develops T-Stat and other NIRS-based tissue oximetry devices used in surgical and critical-care settings. Comparable to Kent Imaging in core NIRS tissue oxygenation measurement technology and clinical focus on perfusion and viability assessment.
Emerging players
- Modulated Imaging: Modulated Imaging developed the Clarifi Imaging System using spatial frequency domain imaging for tissue oxygenation and perfusion assessment, overlapping with Kent's SnapshotNIR in clinical application (perfusion imaging) while using a different imaging modality (SFDI vs NIRS).
Broad incumbents
- Masimo: Masimo is a global leader in pulse oximetry and patient monitoring technologies. While not a direct competitor in NIRS tissue imaging, Masimo's SET pulse oximetry platform competes for the same clinical budget and clinician workflow attention in oxygenation monitoring.
- Medtronic: Medtronic offers the INVOS cerebral/somatic oximetry system using NIRS technology for tissue oxygenation monitoring in surgical and ICU settings. INVOS is an established competitor in the broader tissue oximetry category in which Kent Imaging operates.
- Edwards Lifesciences: Edwards Lifesciences provides FloTrac and other advanced patient monitoring solutions including tissue oximetry through acquired platforms. Edwards competes for hospital capital and monitoring-budget dollars relevant to Kent's perfusion and oxygenation monitoring use cases.
- Nonin Medical: Nonin Medical is a long-established manufacturer of pulse oximeters and regional oximetry sensors. Comparable to Kent in oxygen-saturation monitoring technology, with overlapping clinical customers in wound care and vascular assessment.
Others
- Hamamatsu Photonics: Hamamatsu Photonics manufactures advanced photonic sensors, detectors, and imaging components used in medical and scientific imaging applications — an enabling supplier/ecosystem participant in the multispectral and NIR imaging category where Kent Imaging competes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Kent Imaging social profiles
Digital presenceKent Imaging compliance and trust
Trust signalCompliance4 records
Kent Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kent Imaging leadership team
Management profileNumber of profiles
Profiles11 records
Kent Imaging funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kent Imaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kent Imaging
What does Kent Imaging do?
Kent Imaging designs, manufactures, and markets near-infrared spectroscopy (NIRS) imaging devices, primarily the handheld SnapshotNIR device that measures tissue oxygen saturation (StO2) and hemoglobin trends in microcirculation, and the SnapshotGLO fluorescence imaging device for non-invasive bacterial bioburden detection at the bedside. These devices serve wound care, vascular disease assessment, and reconstructive surgery applications in healthcare facilities.
Is Kent Imaging a public or private company?
Kent Imaging is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kent Imaging founded?
Kent Imaging was founded in 2006. It employs 11 to 50 people.
Where is Kent Imaging based?
Kent Imaging is headquartered in Calgary, Canada, in the North America region.
How does Kent Imaging make money?
One revenue line is on record: medical Device Sales (SnapshotNIR and SnapshotGLO).
Who are Kent Imaging's main competitors?
Direct peers on record are MolecuLight, HyperMed Imaging, WoundVision and Spectros Corporation. Modulated Imaging is listed as an emerging player. Broad incumbents are Masimo, Medtronic, Edwards Lifesciences and Nonin Medical. Hamamatsu Photonics is listed as an others.
Does Kent Imaging have an API?
No public API is recorded for Kent Imaging.
What industry is Kent Imaging in?
Kent Imaging's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 339112 and its SIC code is 3841.